V114 and Acute Otitis Media (V114-032/PNEU-ERA)

Condition:   Acute Otitis Media (AOM) Interventions:   Biological: V114;   Other: Pediatric vaccines Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

AbstractAll infective bacterial species need to conquer the innate immune system in order to colonize and survive in their hosts. The human respiratory pathogensHaemophilus influenzae andMoraxella catarrhalis are no exceptions, and have developed sophisticated mechanisms to evade complement ÔÇÉmediated killing. Both bacterial species carry lipooligosaccharides preventing complement attacks, and attract and utilize host complement regulators C4b binding protein and Factor H to inhibit the classical and alternative pathways of complement activation, respectively. In addition, the regulat or of the terminal pathway of complem...
Source: FEBS Letters - Category: Biochemistry Authors: Tags: REVIEW ARTICLE Source Type: research
Blue Water Vaccines Inc., a Norwood startup, has entered into an exclusive worldwide license agreement with St. Jude Children ’s Research Hospital to develop a vaccine for Streptococcus pneumoniae. The bacteria can cause many kinds of diseases, including the lung infection pneumonia. “A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as acute otitis media, acute bacterial sinusitis and pneumonia,” Blue Water…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Conclusion Micro-otoscopy should be included in the routine work-up of any suspected adult meningitis, because OgM is underdiagnosed. Unlike their impact on pediatric otitis media, PCVs did not change the epidemiology and bacteriology of OgM. [...] Thieme Revinter Publicações Ltda Rio de Janeiro, BrazilArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: International Archives of Otorhinolaryngology - Category: ENT & OMF Authors: Tags: Original Research Source Type: research
Abstract Otitis media (OM) is a very common pediatric disease and nontypeable Haemophilus influenzae (NTHI) is the predominant causative agent. We've developed a chimeric immunogen, chimV4, that simultaneously targets two NTHI adhesins, OMP P5 and the type IV pilus. Transcutaneous immunization (TCI) via bandaid with chimV4 plus the adjuvant dmLT provides significant protection against experimental NTHI-induced OM in chinchilla models. Herein, we now examined the durability and boostability of the induced immune response. Bandaid immunization with chimV4+dmLT followed by two sequential middle ear challenges with NT...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Opisthotonos, extreme involuntary neck and back extension, is rarely seen in modern emergency departments. Vaccines have prevented the most common causes of this clinical presentation. Alternatively, otitis media is one of the most common pediatric infections and is characteristically non-invasive and harmless. In exceedingly rare cases, otitis media can develop complications and progress to invasive pneumococcal diseases including mastoiditis and meningitis. Streptococcus pneumoniae accounts for the majority of otitis media infections, however, since the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) a...
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research
Conclusions: Presence of bacterial otopathogen, specifically nontypeable H. influenzae, in the middle ear during VTI was a predictor of children at-risk of repeat VTI. Here, we identify a modifiable microbiologic factor for repeat VTI that can be targeted to improve clinical management of rAOM.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Original Studies Source Type: research
Conclusion: According to WHO-recommended thresholds for interpreting cost-effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective. PMID: 31774134 [PubMed - in process]
Source: Eastern Mediterranean Health Journal - Category: Middle East Health Tags: East Mediterr Health J Source Type: research
CONCLUSION: Combined data from 11 hospital and community-based studies of children aged less than 18 years who lived in communities with a high burden of acute and chronic respiratory illness showed that RSV was second only to HRV as the most prevalent virus detected across all settings. RSV was the most frequently detected virus in infants hospitalised with bronchiolitis, including those aged less than 6 months. In contrast, RSV was uncommonly detected in children in community settings. In northern Australia, effective maternal and infant RSV vaccines could substantially reduce RSV bronchiolitis-related hospitalisations, ...
Source: Rural and Remote Health - Category: Rural Health Tags: Rural Remote Health Source Type: research
Conclusion: In northern Australia, effective maternal and infant RSV vaccines could substantially reduce RSV bronchiolitis-related hospitalisations, including admissions of Indigenous infants.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Paediatric respiratory epidemiology Source Type: research
More News: Otitis | Otitis Media | Pediatrics | Research | Vaccines